Delhi HC Refuses Interim Injunction in Semaglutide Dispute

Introduction On 2 December 2025 the Delhi High Court refused an interim injunction sought by Danish pharmaceutical company Novo Nordisk against Dr. Reddy’s Laboratories, allowing the latter to continue manufacture and export of semaglutide. The decision turned on contested questions about the validity and scope of Novo Nordisk’s patent filings — the court observed that the company appeared to have secured two separate patents directed to essentially the same compound. The ruling is legally important because it brings into sharp focus the courts’ approach to preliminary relief in high‑stakes pharmaceutical patent disputes: the balance between protecting patent exclusivity and safeguarding competition, patient access and orderly commercial activity pending final adjudication.

Legal background Interim injunctive relief in India traditionally rests on the tri-partite test of (i) a prima facie case in favour of the plaintiff, (ii) balance of convenience, and (iii) whether refusal would cause irreparable injury. Those principles track the English American Cyanamid test (American Cyanamid [1975] AC 396) and have been applied in numerous Indian patent and pharmaceutical disputes. The Patents Act, 1970 confers exclusive rights on patentees (see Section 48) but also contemplates public interest considerations and post‑grant challenges to validity. Indian courts have frequently scrutinised patent monopolies in pharma — for example, in litigation where validity is closely contested the courts have been hesitant to grant blanket interim relief if the patent’s strength is doubtful or if the balance of convenience favours continued supply (see relevant jurisprudence, e.g., Natco Pharma-related decisions and recent Delhi High Court authority analysing balance of convenience in pharmaceutical matters).

Critical analysis The Delhi High Court’s refusal to grant interim relief reflects a careful application of the three‑fold test to the particular factual matrix of this case. The threshold question was whether Novo Nordisk had established a strong prima facie case that Dr. Reddy’s manufacturing and exportation infringed a valid and subsisting monopoly. The court recorded concerns of “double patenting” — that is, two patents claiming the same inventive subject‑matter — which directly undermines the clarity and exclusivity a patentee must demonstrate to secure interlocutory protection.

Double patenting (or patent proliferation) can erode the public notice function of the patent register and weaken claims of exclusivity. If a patentee files successive claims that seek de facto extension of monopoly through overlapping rights, courts and patent offices will treat the grants with scepticism. Where the validity or scope of the asserted patent is open to serious question, the prima facie case requirement is weakened and the court must weigh whether an injunction would cause disproportionate harm to the defendant and to third parties (including patients and purchasers), especially where the defendant’s activities are limited to export to jurisdictions in which the patentee’s monopoly may not subsist. (Note: whether Dr. Reddy’s exports were intended for markets where Novo Nordisk holds no patent rights is a factual detail not fully set out in the public report and is marked here as hypothetical.)

The balance of convenience also appears to have favoured the defendant. Interim injunctions in pharmaceuticals frequently have market‑wide effects: stopping manufacture and export can disrupt supply chains, employment and contractual relations and may prejudge commercial markets permanently even if the patentee ultimately succeeds. Conversely, an injunction where validity is doubtful may improperly chill legitimate competition and innovation.

Finally, the irreparable injury limb requires more than speculative loss of market share. Monetary compensation is generally considered an adequate remedy where a patent is finally held valid. The Court’s reluctance to find irreparable harm was consistent with the observation that the asserted patents’ enforceability and scope were not free from doubt.

This approach aligns with recent Indian authority in which courts have refused interim relief where the strength of the patent claim was uncertain or where public interest considerations weighed heavily. While patentees remain entitled to protection, courts will not allow that entitlement to operate as a blunt instrument to freeze commerce where the legal basis for exclusivity is contested.

Opinion and outlook Practitioners and rights‑holders should expect Indian courts to continue a nuanced, fact‑sensitive stance on interlocutory relief in pharma patent disputes. The semaglutide decision emphasises that (1) patentees must present clear, unambiguous claim construction and chain of title at the interlocutory stage; (2) the doctrine against double patenting is a potent defence and will be scrutinised; and (3) public interest, including access to medicines and continuity of supply, will inform the balance of convenience calculus.

For patent owners, the ruling is a reminder to use the patent office’s prosecution process to consolidate claims and avoid overlapping filings that may later be characterised as double patenting. For generics and contract manufacturers, the decision provides some interim reassurance that contested patents will not automatically result in injunctive freezes. Regulators and policy‑makers might also take this occasion to consider procedural measures: expedited validity proceedings in essential‑medicine cases, clearer guidelines on double patenting, and improved transparency on export consignments where patent rights do not apply.

Conclusion The Delhi High Court’s refusal to grant an interim injunction in the semaglutide dispute is a measured application of established principles: where patent validity or exclusivity is in doubt — particularly due to alleged double patenting — courts will hesitate to grant interlocutory protection that could unduly impede competition and access. The case underscores the importance for patentees to present clean, cogent claims at the outset and signals that Indian courts will balance private monopoly claims against broader public and commercial interests pending final determination.

(Note: some factual aspects — such as the precise targets of Dr. Reddy’s exports and the full content of Novo Nordisk’s patents — are not exhaustively reported in the public news summary and have been identified as hypothetical where relevant.)